The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the numbers so you can assess that for yourself. Pfizer's share price last ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.